Abstract
Prescription drugs have become a major category of abused substances, and there is evidence that the prevalence of prescription drug abuse may soon overtake that of illicit drugs. Study of prescription drugs has been hampered by vague terminology, since prescription drugs are only separated from other drugs of abuse by social and legal constructs. Reviewed herein is published literature on the abuse of four major categories of abused prescription drugs: sedative-hypnotics, stimulants, anabolic steroids, and anticholinergics. The review emphasizes evidence regarding the effects of these drugs on neural systems. Other abused prescription drugs that fall outside of the major categories are also briefly addressed.
Similar content being viewed by others
References
Abernethy, M. K., & Becker, L. B. (1992). Acute nutmeg intoxication. The American Journal of Emergency Medicine, 10, 429–430.
Alen, M., Rahkila, P., Reinila, M., & Vihko, R. (1987). Androgenic-anabolic steroid effects on serum thyroid, pituitary and steroid hormones in athletes. The American Journal of Sports Medicine, 15, 357–361.
Alen, M., Reinila, M., & Vihko, R. (1985). Response of serum hormones to androgen administration in power athletes. Medicine and Science in Sports and Exercise, 17, 354–359.
Allison, C. & Pratt, J. (2003). Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence. Pharmacology & Therapeutics, 98, 171–195.
American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders, fourth edition, text-revision (DSM-IV-TR). Washington, D.C.: American Psychiatric Association.
Aragona, M. (2000). Abuse, dependence, and epileptic seizures after zolpidem withdrawal: review and case report. Clinical Neuropharmacology, 23, 281–283.
Arvary, D., & Pope, H. G. Jr. (2000). Anabolic steroids: a possible gateway to opioid dependence? The New England Journal of Medicine, 342, 1532.
Bagatell, C. J., & Bremner, W. J. (1996). Androgens in men—uses and abuses. The New England Journal of Medicine, 334, 707–714.
Bahrke, M. S., Yesalis, C. E., Kopstein A. N., & Nyberg, F. (2000). Risk factors associated with anabolic-androgenic steroid use among adolescents. Sports Medicine, 29, 397–405.
Barker, M. J., Greenwood, K. M., Jackson, M., & Crowe, S. F. (2004a). Cognitive effects of long-term benzodiazepine use: A meta-analysis. CNS Drugs, 18, 37–48.
Barker, M. J., Greenwood, K. M., Jackson, M., & Crowe, S. F. (2004b). Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: A meta-analysis. Archives of Clinical Neuropsychology, 19, 437–454.
Barrett, S. P., Darredeau, C., Bordy, L. E., & Pihl, R. O. (2005). Methylphenidate misuse in a university student sample. Canadian Journal of Psychiatry, 50, 457–461.
Barrett, S. P., & Pihl, R. O. (2002). Oral methylphenidate-alcohol co-abuse. Journal of Clinical Psychopharmacology, 22, 633–634.
Basaria, S., Wahlstrom, J. T., & Dobs, A. S. (2001). Anabolic-androgenic steroid therapy in the treatment of chronic diseases. The Journal of Clinical Endocrinology and Metabolism, 86, 5108–5117.
Bateson, A. N. (2002). Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal. Current Pharmaceutical Design, 8, 5–21.
Batten, H. L., Prottas, J. M., Horgan, C. M., Prottas, J. M., Simon, L. J., Larson, M. J., et al. (1993). Drug services research survey. Phase II final report. Submitted to the National Institute on Drug Abuse. Waltham: Institute for Health Policy, Brandeis University.
Bhasin, S., Storer, T. W., Berman, N., Callegari, C., Clevenger, B., Phillips, J., et al. (1996). The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. The New England Journal of Medicine, 335, 1–7.
Biederman J. (2003). Pharmacology for attention deficit hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from longitudinal follow-up of youths with and without ADHD. The Journal of Clinical Psychiatry, 64(Suppl. 11), 3–8.
Biederman, J., Wilens, T., Mick, E., Milberger, S., Spencer, T. J., & Faraone, S. V. (1995). Psychoactive substance use disorder in adults with attention deficit hyperactivity disorder: Effects of ADHD and psychiatric comorbidity. The American Journal of Psychiatry, 152, 1652–1658.
Bolin, R. R. (1960). Psychiatric manifestations of Artane toxicity. The Journal of Nervous and Mental Disease, 131, 256–259.
Bollinger, L. C., Bush, C., Califano, J. A., Chenault, K. I., Curtis, J. L., Dimon, J., et al. (2005). Under the counter. The diversion and abuse of controlled prescription drugs in the U.S. New York: The National Center on Addiction and Substance Abuse at Columbia University (CASA).
Boyd, C. J., McCabe, S. E., Cranford, J. A., & Young, A. (2006). Adolescents’ motivations to abuse prescription medications. Pediatrics, 118, 2472–2480.
Bramness, J. G., Skurtveit, S., & Morland, J. (2004). Impairment due to intake of carisoprodol. Drug and Alcohol Dependence, 74, 311–318.
Britt, G. C., & McCance-Katz, E. F. (2005). A brief overview of the clinical pharmacology of “club drugs.” Substance Use & Misuse, 40, 1189–1201.
Brower, K. J. (2000). Assessment and treatment of anabolic steroid abuse, dependence, and withdrawal. C. E. Yesalis (Ed.), Anabolic steroids in sport and exercise (2nd ed.). Champagne: Human Kinetics.
Brower, K. J. (2002). Anabolic steroid abuse and dependence. Current Psychiatry Reports, 4, 377–387.
Buckley, W. E., Yesalis, C. E., Friedl, K. E., Anderson, W., Streit, A. L., & Wright, J. E. (1988). Estimated prevalence of anabolic steroid use among male high school seniors. JAMA: The Journal of the American Medical Association, 260, 3441–3445.
Buhrich, N., Weller, A., & Kevans, P. (2000). Misuse of anticholinergic drugs by people with serious mental illness. Psychiatric Services, 51, 928–929.
Cami, J., & Farre, M. (2003). Mechanisms of disease: Drug addiction. The New England Journal of Medicine, 349, 975–986.
Carlini, E. A. (1993). Preliminary note: Dangerous use of anticholinergic drugs in Brazil. Drug and Alcohol Dependence, 32, 1–7.
Challman, T. D., & Lipsky, J. J. (2000). Methylphenidate: Its pharmacology and uses. Mayo Clinic Proceedings, 75, 711–721.
Choi, P. Y. L., Pope, H. G. Jr., & Olivardia, R. (2002). Muscle dysmorphia: A new syndrome in weightlifters. British Journal of Sports Medicine, 36, 375–377.
Clark, H. W., & Bizzelli, A. C. (2005). A federal perspective on the abuse of prescription stimulants. Psychiatric Annals, 35, 261–263.
Cohen, L. A., Jhung, M. A., & Budnitz, D. S. (2006). Stimulant medications and attention deficit-hyperactivity disorder. The New England Journal of Medicine, 354, 2294–2295.
Compton, W. M., & Volkow, N. D. (2005). Abuse of prescription drugs and the risk of addiction. Drug and Alcohol Dependence, 83S, S4–S7.
Congeni, J., & Millier, S. (2002). Supplements and drugs used to enhance athletic performance. Pediatric Clinics of North America, 49, 435–461.
Crawshaw, J. A., & Mullen, P. E. (1984). A study of benzhexol abuse. The British Journal of Psychiatry, 145, 300–303.
Crouch, B. I., Caravati, E. M., & Booth, J. (2004). Trends in child and teen nonprescription drug abuse reported to a regional poison control center. American Journal of Health-system Pharmacy, 61, 1252–1257.
Darcourt, G., Pringuey, D., Salliere, D., & Lavoisy, J. (1999). The safety and tolerability of zolpidem—an update. Journal of Psychopharmacology, 13, 81–93.
DeFrates, L. J., Hoehns, J. D., Sakornbut, E. L., Glascock, D. G., & Tew, A. R. (2005). Antimuscarinic intoxication resulting from the ingestion of moonflower seeds. The Annals of Pharmacotherapy, 39, 173–176.
Fisch, R. Z. (1987). Trihexyphenidyl abuse: Therapeutic implications for negative symptoms of schizophrenia? Acta Psychiatrica Scandinavica, 75, 91–94.
Forman, R. F., Woody, G. E., McLellan, T., & Lynch, K. G. (2006). The availability of web sites offering to sell opioid medications without prescriptions. The American Journal of Psychiatry, 163, 1233–1238.
Friedman, R. A. (2006). The changing face of teenage drug abuse – the trend toward prescription drugs. The New England Journal of Medicine, 354, 1448–1450.
Fryburg, D. A. (1994). Insulin-like growth factor I exerts growth hormone- and insulin-like actions on human muscle protein metabolism. The American Journal of Physiology, 267, E331–E336.
Fu, C. H. Y., Abel, K. M., Allin, M. P. G., Gasston, D., Costafreda, S. G., Suckling, J., et al. (2005). Effects of ketamine on prefrontal and striatal regions in an overt verbal fluency task: A functional magnetic resonance imaging study. Psychopharmacology, 183, 92–102.
Garland, J. E. (1998). Intranasal abuse of prescribed methylphenidate. Journal of the American Academy of Child & Adolescent Psychiatry, 37, 573–574.
Goggin, D. A., & Solomon, G. F. (1979). Trihexyphenidyl abuse for euphorigenic effect. The American Journal of Psychiatry, 136, 459–460.
Goldman, L. S., Genel, M., Bezman, R. J., & Slanetz, P. J. (1998). Diagnosis and treatment of attention deficit/hyperactivity disorder in children and adolescents. JAMA: The Journal of the American Medical Association, 279, 1100–1107.
Goldstein, P. (1990). Anabolic steroids: an ethnographic approach. Anabolic steroid abuse, NIDA research monograph. Rockville: NIDA.
Gonzalez-Cadavid, N. F., Tayler, W. E., Yarasheski, K., Sinha-Hikim, I., Ma, K. Ezzat, S., et al (1998). Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proceedings of the National Academy of Sciences of the United States of America, 95, 14938–14943.
Goodwin, R. D., & Hasin, D. S. (2002). Sedative use and misuse in the United States. Addiction, 97, 555–562.
Gopel, C., Laufer, C., & Marcus, A. (2002). Three cases of angel’s trumpet tea-induced psychosis in adolescent substance abusers. Nordic Journal of Psychiatry, 56, 49–52.
Greenhill, L. (2005). The science of stimulant abuse. Psychiatric Annals, 35, 210–214.
Gurley, R. J., Aranow, R., & Katz, M. (1998). Medicinal marijuana: A comprehensive review. Journal of Psychoactive Drugs, 30, 137–147.
Hadidi, K. A. (2004). Development of a screening method for the most commonly abused anticholinergic drugs in Jordan; trihexyphenidyl, procyclidine, and biperiden. Legal Medicine (Tokyo, Japan), 6, 233–241.
Hajak, G., Muller, W. E., Wittchen, H. U., Pittrow, D., & Kirch, W. (2003). Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: A review of case reports and epidemiological data. Addiction, 98, 1371–1378.
Hemmelgarn, B., Suissa, S., Huang, A., Boivin, J. F., & Pinard, G. (1997). Benzodiazepine use and the risk of motor vehicle crash in the elderly. Journal of the American Medical Association, 278, 27–31.
Hickson, R. C., Czerwinski, S. M., Falduto, M. T., & Young, A. P. (1990). Glucocorticoid antagonism by exercise and androgenic-anabolic steroids. Medicine and Science in Sports and Exercise, 22, 331–340.
Huang, B., Dawson, D. A., Stinson, F. S., Hasin, D. S., Ruan, W. J., Saha, T. D., et al. (2006). Prevalence, correlates, and comorbidity of nonmedical prescription drug use and drug use disorders in the United States: Results of the National Epidemiological Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry, 67, 1062–1073.
Hussain, M. Z., Waheed, W., & Hussain, S. (2005). Intravenous quetiapine abuse. The American Journal of Psychiatry, 162, 1755–1756.
Hutchinson, M. A., Smith, P. F., & Darlington, C. L. (1996). The behavioural and neuronal effects of the chronic administration of benzodiazepine anxiolytic and hypnotic drugs. Progress in Neurobiology, 49, 73–97.
Isaacson, J. H., Hopper, J. A., Alford, D. P., & Parran, T. (2005). Prescription drug use and abuse. Risk factors, red flags, and prevention strategies. Postgraduate Medicine, 118, 19–26.
Isbister, G. K., Oakley, P., Dawson, A. H., & Whyte, I. M. (2003). Presumed Angel’s trumpet (Brugmansia) poisoning: Clinical effects and epidemiology. Emergency Medicine (Fremantle, W.A.), 15, 376–382.
Jadad, A. R., Boyle, M., Cunningham, C., Kim, M., & Schachar, R. (1999). Treatment of attention deficit hyperactivity disorder. Agency for Healthcare Research and Quality, US Department of Health and Human Services. Retrieved March 30, 2007, from http://www.ncbi.nih.gov/books/bv.fcgi?rid=hstat1.chapter.14677.
Jellinek, T. (1977). Mood elevating effect of trihexyphenidyl and biperiden in individuals taking antipsychotic medication. Diseases of the Nervous System, 38, 353–355.
Johnston, L. D., O’Malley, P. M., Bachman, J. G., & Schulenberg, J. E. (2005). Monitoring the future national survey results on drug use, 1975–2004, vol. I: Secondary school students. Bethesda: National Institute on Drug Abuse.
Kanayama, G., Barry, S., Hudson, J. I., & Pope, H. G. Jr. (2006). Body image and attitudes toward male roles in anabolic-androgenic steroid users. The American Journal of Psychiatry, 63, 697–703.
Kanayama, G., Pope, H. G. Jr., Cohane, G., & Hudson, J. I. (2003). Risk factors for anabolic-androgenic steroid use among weightlifters: A case-control study. Drug and Alcohol Dependence, 71, 77–86.
Kanayama, G., Pope, H.G. Jr., & Hudson, J. I. (2001). “Body image” drugs: A growing psychosomatic problem. Psychotherapy and Psychosomatics, 70, 61–65.
Kaminer, Y., Munitz, H., & Wijsenbeek, H. (1982). Trihexyphenidyl (Artane) abuse: euphoriant and anxiolytic. The British Journal of Psychiatry, 140, 473–474.
Katzung, B. G. (1986). Basic and clinical pharmacology. Norwalk: Lange Medical Publications.
Katzung, B. G. & Trevor, A. J. (1998). Sedative-hypnotic drugs. In Examination and board review pharmacology (pp. 171–178). New York: McGraw-Hill.
Kouri, E., Lukas, S. E., Pope, H. G. Jr, & Oliva, P. S. (1995). Increased aggressive responding in male volunteers following the administration of gradually increasing doses of testosterone cypionate. Drug and Alcohol Dependence, 40, 73–79.
Kouri, E., Pope, H. G. Jr, Katz, D. L., & Oliva, P. (1995). Fat-free mass index in users and non-users of anabolic-androgenic steroids. Clinical Journal of Sport Medicine, 5, 223–228.
Kripke, D. F., Klauber, M. R., Wingard, D. I., & Fell, R. L. (1998). Mortality hazards associated with prescription of hypnotics. Biological Psychiatry, 43, 687–693.
Kroutil, L. A., Van Brunt, D. L., & Herman-Stahl, M. A. (2006). Nonmedical use of prescription stimulants in the United States. Drug and Alcohol Dependence, 84, 135–143.
Krystal, J. H., Staley, J., Mason, G., Petrakis, I. L., Kaufman, J., Harris, R. A., et al. (2006). Gamma-aminobutyric acid type A receptors and alcoholism: Intoxication, dependence, vulnerability, and treatment. Archives of General Psychiatry, 63, 957–968.
Land, W., Pinsky, D., & Salzman, C. (1991). Abuse and misuse of anticholinergic medications. Hospital & Community Psychiatry, 42, 580–581.
Lowry, T. P. (1977). Trihexyphenidyl abuse. The American Journal of Psychiatry, 134, 1315.
Malcolm, R. J. (2003). GABA systems, benzodiazepines, and substance dependence. The Journal of Clinical Psychiatry, 64, 36–40.
Malone, D. A. Jr., & Dimeff, R. J. (1992). The use of fluoxetine in depression associated with anabolic steroid withdrawal: A case series. The Journal of Clinical Psychiatry, 53, 130–132.
Malone, D. A. Jr., Dimeff, R. J., & Lombardo, J. A. (1995). Psychiatric effects and psychoactive substance use in anabolic-androgenic steroid abusers. Clinical Journal of Sport Medicine, 5, 223–228.
Manchikanti, L. (2006). Prescription drug abuse: What is being done to address this new drug epidemic? Testimony before the Subcommittee on Criminal Justice, Drug Policy, and Human Resources. Pain Physician, 9, 287–321.
Manchikanti, L., Whitfield, E., & Pallone, F. (2005). Evolution of the National All Schedules Prescription Electronic Reporting Act (NASPER): A public law for balancing treatment of pain and drug abuse and diversion. Pain Physician, 8, 335–347.
Markowitz, J. S., Logan, B. K., Diamond, F., & Patrick, K. S. (1999). Detection of a novel metabolite ethylphenidate after methylphenidate overdose with alcohol coingestion. Journal of Clinical Psychopharmacolology, 19, 362–366.
Marriott, P. (1976). Dependence on antiparkinsonian drugs. British Medical Journal, 1(6002), 152.
Matochik, J., Nordahl, T., & Gross, M. (1993). Effects of acute stimulant medication on cerebral metabolism on cerebral metabolism in adults with hyperactivity. Neuropsychopharmacology, 8, 377–386.
Maxwell, C. R., Ehrlichman, R. S., Liang, Y, Trief, D., Kanes, S. J., Karp, J., et al. (2006). Ketamine produces lasting disruptions in encoding of sensory stimuli. The Journal of Pharmacology and Experimental Therapeutics, 316, 315–324.
McCabe, S. E., Knight J. R., Teter, C. J., & Weschler, H. (2005). Nonmedical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction, 99, 96–106.
McCabe, S. E., Teter, C. J., & Boyd, C. J. (2004). The use, misuse a new version of prescription stimulants among middle and high school students. Substance Use and Misuse, 39, 1095–1117.
McCabe, S. E., Teter, C. J., & Boyd, C. J. (2006). Medical use, illicit use, and diversion of abusable prescription drugs. Journal of American College Health, 54, 269–278.
McInnis, M., & Petursson, H. (1984). Trihexyphenidyl dependence. Acta Psychiatrica Scandinavica, 69, 538–542.
McInnis, M., & Petursson, H. (1985). Withdrawal of trihexyphenidyl. Acta Psychiatrica Scandinavica, 71, 297–303.
Melia, P., Pipe, A., & Greenberg, L. (1996). The use of anabolic-androgenic steroids by Canadian students. Clinical Journal of Sport Medicine, 6, 9–14.
Monitoring the Future (2003). Data from in school surveys of eighth, 10th, and 12th grade students. Drug and alcohol press release: Trends in use of various drugs. Retrieved on March 30, 2007, from http://www.monitoringthefuture.org/data/03data/pr03t1.pdf.
Morgan, W. W. (1990). Abuse liability of barbiturates and other sedative-hypnotics. Advances in Alcohol and Substance Abuse, 9, 67–82.
Morgan, C. J. A., & Curran H. V. (2006). Acute and chronic effects of ketamine upon human memory: A review. Psychopharmacology, 188, 408–424.
Morin, C. M., Bastien, C., Guay, B., Radouco-Thomas, M., Leblanc, J., & Vallieres, A. (2004). Randomized clinical trial of supervised tapering and cognitive behavioral therapy to facilitate benzodiazepine discontinuation in older adults with chronic insomnia. The American Journal of Psychiatry, 161, 332–342.
Morris, M. C., Cline R. J., Weiler R. M., & Broadway S. C. (2006). Prescription drug abuse information in D.A.R.E. Journal of Drug Education, 36, 33–45.
Nappo, S. A., de Oliveira, L. G., Sanchez, Z. M., & Carlini, E. A. (2005). Trihexyphenidyl (Artane): A Brazilian study of its abuse. Substance Use & Misuse, 40, 473–482.
Narendran, R., Frankle, W. G., Keefe, R., Gil, R., Martinez, D., Slifstein, M., et al. (2005). Altered prefrontal dopaminergic function in chronic recreational ketamine users. The American Journal of Psychiatry, 162, 2352–2359.
O’Brien, C. P. (2005). Benzodiazepine use, abuse, and dependence. The Journal of Clinical Psychiatry, 66, 28–33.
Olfson, M., Gameroff, M. J., Marcus, S. C., & Jensen, P. S. (2003). National trends in the treatment of attention deficit hyperactivity disorder. The American Journal of Psychiatry, 160, 1071–1077.
Olivardia, R., Pope, H. G., & Hudson, J. I . (2000). Muscle dysmorphia in male weightlifters: A case-control study. The American Journal of Psychiatry, 157, 1291–1296.
Oude Voshaar, R. C., Couvee, J. E., Van Balkom, A. J., Mulder, P. G., & Zitman, F. G. (2006). Strategies for discontinuing long-term benzodiazepine use: Meta-analysis. The British Journal of Psychiatry, 189, 213–220.
Parrott, A. C., Choi, P. Y. L., & Davies, M. (1994). Anabolic steroid use by amateur athletes: Effects upon psychological mood states. The Journal of Sports Medicine and Physical Fitness, 34, 292–298.
Pierre, J. M., Shnayder, I., Wirshing, D. A., & Wirshing, W. C. (2004). Intranasal quetiapine abuse. The American Journal of Psychiatry, 161, 1718.
Pinta, E. R., & Taylor, R. E. (2007). Quetiapine addiction? The American Journal of Psychiatry, 164, 174.
Pittinger, C., & Desan, P. H. (2007). Gabapentin abuse, and delirium tremens upon gabapentin withdrawal. The Journal of Clinical Psychiatry, 68, 483–484.
Pope, H. G. Jr & Brower, K. J. (2004). Anabolic-androgenic steroids. In Textbook of substance abuse treatment (3rd ed.). Washington, D.C.: American Psychiatric Publishing Inc.
Pope, H. G. Jr., & Katz, D. L. (1994). Psychiatric and medical effects of anabolic-androgenic steroid abuse: a controlled study of 160 athletes. Archives of General Psychiatry, 51, 375–382.
Pope, H. G. Jr., & Katz, D. L. (2003). Psychiatric effects of exogenous anabolic-androgenic steroids. In Psychoneuroendocrinology. Washington, D.C.: American Psychiatric Publishing, Inc.
Pope, H. G. Jr., Kouri, E., & Hudson, J. I. (2000). Effects of supraphysiologic doses of testosterone on mood and aggression in normal men. Archives of General Psychiatry, 57, 133–140.
Porcerelli, J. H., & Sandler, B. A. (1998). Anabolic-androgenic steroid abuse and psychopathology. The Psychiatric Clinics of North America, 21, 829–833.
Rabkin, J. G., Wagner, G. J., & Rabkin, R. (2000). A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Archives of General Psychiatry, 57, 141–147.
Ravishankar, A., & Carnwath, T. (1998). Zolpidem tolerance and dependence—two case reports. Journal of Psychopharmacology, 12, 103–104.
Ray, W. A., Griffin, M. R., Schaffner, W., Bauth, D. K., & Melton, L. J. (1987). Psychotropic drug use and the risk of hip fracture. The New England Journal of Medicine, 316, 363–369.
Reeves, R. R., Carter, O. S., Pinkofsky, H. B., Struve, F. A., & Bennett, D. M. (1999). Carisoprodol (Soma): Abuse potential and physician unawareness. Journal of Addictive Diseases, 18, 51–56.
Robins, L. N., & Regier, D. A. (Eds.) (1991). Psychiatric disorders in America. New York: The Free Press.
Rouchell, A. M., & Dixon S. P. (1977). Trihexyphenidyl abuse. The American Journal of Psychiatry, 134, 1315.
Rubinstein, J. S. (1978). Abuse of antiparkinsonism drugs: feigning of extrapyramidal symptoms to obtain trihexyphenidyl. JAMA: The Journal of the American Medical Association, 239, 2365–2366.
Rubinstein, J. S. (1978). Abuse of anticholinergic drugs. The New England Journal of Medicine, 299, 834.
Rush, C. R., Baker, R. W., & Wright, K. (1999). Acute behavioral effects and abuse potential of trazodone, zolpidem, and triazolam in humans. Psychopharmacology, 144, 220–233.
Rust, G. S., Hatch, R., & Gums, J. G. (1993). Carisoprodol as a drug of abuse. Archives of Family Medicine, 2, 429–432.
Sareen, J., Enns, M. W., & Cox, B. J. (2004). Potential for misuse of sedatives. The American Journal of Psychiatry, 161, 1723.
Sattar, S. P., Bhatia, S. C., & Petty, F. (2004). Potential benefits of quetiapine in the treatment of substance dependence disorders. Journal of Psychiatry and Neuroscience, 29, 452–457.
Schuster, C. R. (2006). History and current perspectives on the use of drug formulations to decrease the abuse of prescription drugs. Drug and Alcohol Dependence, 83S, S8–S14.
Sessa, B. (2007). Is there a case for MDMA-assisted psychotherapy in the UK? Journal of Psychopharmacology, 21, 220–224.
Simoni-Wastila, L., & Yang, H. K. (2006). Psychoactive drug abuse in older adults. The American Journal of Geriatric Pharmacotherapy, 4, 380–394.
Smith, J. M. (1980). Abuse of the antiparkinson drugs: a review of the literature. The Journal of Clinical Psychiatry, 41, 351–354.
Smith, M. (2006). Cardiovascular safety warning added for stimulants ffor ADHD. Retrieved March 26, 2007, from http://www.medpagetoday.com/ProductAlert/Prescriptions/tb2/3987.
Soyka, M., Bottlender, R., & Moller, H. J. (2000). Epidemiological evidence for low abuse potential of zolpidem. Pharmacopsychiatry, 33, 138–141.
Stern, T. A. (1983). Continuous infusion of physostigmine in anticholinergic delirium: Case report. The Journal of Clinical Psychiatry, 44, 463–464.
Stewart, S. A. (2005). The effects of benzodiazepines on cognition. The Journal of Clinical Psychiatry, 66, 9–13.
Stilger, V. G., & Yesalis, C. E. (1999). Anabolic-androgenic steroid use among high school football players. Journal of Community Health, 24, 131–145
Su, T.-P., Pagliaro, M., & Schmidt, P. J. (1993). Neuropsychiatric effects of anabolic steroid in male normal volunteers. JAMA: The Journal of the American Medical Association, 269, 2760–2764.
Substance Abuse and Mental Health Services Administration (2003). Results from the 2002 national survey on drug use and health: National findings (NSDUH Series H-22, DHHS publication no. sma 03–3836). Rockville: Office of Applied Sciences.
Taylor, S., McCracken, C. F., Wilson, J. C., & Copeland, J. R. (1998). Extent and appropriateness of benzodiazepine use. Results from an elderly urban community. The British Journal of Psychiatry, 173, 433–438.
Teter, C. J., McCabe, S. E., LaGrange, K., Cranford, J. A., & Boyd, C. J. (2006). Illicit use of specific prescription stimulants among college students: Prevalence, motives, and routes of administration. Pharmacotherapy, 26, 1501–1510.
Tincello, D. G., Saunders, P. T., Hodgins, M. B., Simpson, N. B., Edwards, C. R., Hargreaves, T. B., et al. (1997). Correlation of clinical, endocrine and molecular abnormalities with in vivo responses to high-dose testosterone therapy in patients with partial androgen insensitivity syndrome. Clinical Endocrinology, 46, 497–506.
Tokish, J. M., Kocher, M. S., & Hawkins, R. J. (2004). Ergogenic aids: a review of basic science, performance, side effects, and status in sports. The American Journal of Sports Medicine, 32, 543–1553.
Tso, M. M., Blatchford, K. L., Callado, L. F., McLaughlin, D. P., & Stamford, J. A. (2004). Stereoselective effects of ketamine on dopamine, serotonin, and noradrenaline release and uptake in rat brain slices. Neurochemistry International, 44, 1–7.
Victorri-Vigneau, C., Guerlais, M., & Jolliet, P. (2007). Abuse, dependency and withdrawal with gabapentin: A first case report. Pharmacopsychiatry, 40, 43–44.
Volkow, N. D. (2006). Stimulant medications: how to minimize their reinforcing effects? The American Journal of Psychiatry, 163, 387–395.
Volkow, N. D., & Swanson, J. M. (2003). Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. The American Journal of Psychiatry, 160, 1909–1918.
Voshaar, R. C., Gorgels, W. J., Mol, A. J., van Balkom, A. J., Mulder, J., van de Lisdonk, E. H., et al. (2006). Predictors of long-term benzodiazepine abstinence in participants of a randomized-controlled benzodiazepine withdrawal program. Canadian Journal of Psychiatry, 51, 445–452.
Warner, L. A., Kessler, R. C., Hughes, M., Anthony, J. C., & Nelson, C. B. (1995). Prevalences and correlated of drug use and dependences in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry, 52, 219–229.
Wilens, T. E., Faraone, S. V., Biederman, J., & Gunawardene, S. (2003). Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics, 111, 179–185.
Wills, S. (2005). Drugs of abuse. London: Pharmaceutical Press.
Wines, J. D. Jr., Gruber, A. J., Pope, H. G. Jr., & Lukas, S. E. (1999). Nalbuphine hydrochloride dependence in anabolic steroid users. The American Journal on Addictions, 8, 161–164.
Wood, R. I. (2004). Reinforcing aspects of androgens. Physiology and Behavior, 83, 279–289.
Wu, F. C. (1997). Endocrine aspects of anabolic steroids. Clinical Chemistry, 43, 289–1292.
Yates, W. R., Perry, P., MacIndoe, J., Holman, T., & Ellingrod, V. (1999). Psychosexual effects of three doses of testosterone cycling in normal men. Biological Psychiatry, 45, 254–260.
Yesalis, C. E. (1992). Epidemiology and patterns of anabolic-androgenic steroid use. Psychiatric Annals, 22, 7–18.
Zametkin, A. J., Nordahl, T. E., Gross M., King, A. C., Semple, W. E., Rumsey, J., et al. (1990). Cerebral glucose metabolism in adults with hyperactivity of childhood onset. The New England Journal of Medicine, 323, 1361–1366.
Zarocostas, J. (2007). Misuse of prescription drugs could soon exceed that of illicit narcotics, UN panel warns. British Medical Journal, 334, 334.
Zawertailo, L. A., Busto, U. E., Kaplan, H. L., Greenblatt, D. J, & Sellers, E. M. (2003). Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital. Journal of Clinical Psychopharmacology, 23, 269–280.
Zemishlany, Z., Aizenberg, D., Weiner, Z., & Weizman, A. (1996). Trihexyphenidyl (Artane) abuse in schizophrenic patients. International Clinical Psychopharmacology, 11, 199–202.
Author information
Authors and Affiliations
Corresponding author
Appendices
Appendix
DSM-IV Diagnostic Criteria for Substance Abuse/Dependence
Substance Abuse
Substance use resulting in significant impairment or distress, as manifested by at least one of the following, within a 12-month period:
-
1.
recurrent substance use resulting in a failure to fulfill major role obligations at work, school, or home (e.g., repeated absences or poor work performance; absences, suspensions, or expulsions from school; neglect of children or household)
-
2.
recurrent substance use in physically hazardous situations (e.g., driving while intoxicated)
-
3.
recurrent substance-related legal problems
-
4.
continued substance use despite persistent social or relational problems (e.g., arguments with spouse, physical fights)
The symptoms have never met the criteria for Substance Dependence for this class of substance.
Substance Dependence
Substance use, resulting in significant impairment or distress, as manifested by at least three of the following, occurring at any time in the same 12-month period:
-
1.Tolerance,
as demonstrated by:
-
(a)
a requirement for increased amounts of the substance to achieve intoxication or desired effect
-
(b)
diminished effect with continued use of the same amount of the substance
-
(a)
-
2.
Withdrawal, as demonstrated by either of the following:
-
(a)
the characteristic withdrawal syndrome for the substance
-
(b)
the substance, or a similar substance, is taken to relieve or avoid withdrawal symptoms
-
(a)
-
3.
The substance is used in larger amounts or over a longer period than intended
-
4.
A persistent desire or unsuccessful efforts to diminish or control substance use
-
5.
Significant time is spent in activities necessary to obtain the substance (e.g., visiting multiple doctors, driving long distances), use the substance, or recover from its effects
-
6.
Important social, occupational, or recreational activities are reduced or discontinued because of substance use
-
7.
Substance use is continued despite knowledge of a physical or psychological problem that is likely to have been caused or exacerbated by the substance
Adapted from: Diagnostic and statistical manual of mental disorders, fourth edition, text-revision (DSM-IV-TR). (2000). Washington, D.C.: American Psychiatric Association.
Rights and permissions
About this article
Cite this article
Caplan, J.P., Epstein, L.A., Quinn, D.K. et al. Neuropsychiatric Effects of Prescription Drug Abuse. Neuropsychol Rev 17, 363–380 (2007). https://doi.org/10.1007/s11065-007-9037-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11065-007-9037-7